{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:44:34Z","timestamp":1789011874085,"version":"build-2803163510"},"reference-count":104,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":788,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1093\/annonc\/mdx189","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T19:10:53Z","timestamp":1492110653000},"page":"2094-2106","source":"Crossref","is-referenced-by-count":37,"title":["Unmet needs in the first-line treatment of follicular lymphoma"],"prefix":"10.1016","volume":"28","author":[{"given":"C.","family":"Casulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.H.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx189_bb0010","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0015","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0020","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx189_bb0035","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"10.1093\/annonc\/mdx189_bb0040","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdx189_bb0045","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0050","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0055","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx189_bb0060","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1182\/blood-2015-02-625152","article-title":"CD10 delineates a subset of human IL-4 producing follicular helper T cells involved in the survival of follicular lymphoma B cells","volume":"125","author":"Ame-Thomas","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0065","doi-asserted-by":"crossref","first-page":"3904.","DOI":"10.1038\/ncomms4904","article-title":"Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma","volume":"5","author":"Green","year":"2014","journal-title":"Nat Commun"},{"key":"10.1093\/annonc\/mdx189_bb0070","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","article-title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma","volume":"121","author":"Green","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0075","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdx189_bb0080","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw255","article-title":"Recommendations for clinical trial development in follicular lymphoma","volume":"109","author":"Maddocks","year":"2016","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdx189_bb0085","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/leu.2014.91","article-title":"How we manage follicular lymphoma","volume":"28","author":"Hiddemann","year":"2014","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdx189_bb0090","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/annonc\/mds517","article-title":"ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)","volume":"24","author":"Ghielmini","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0095","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0100","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/bjh.13895","article-title":"Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era","volume":"172","author":"Nastoupil","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx189_bb0105","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0110","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0115","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0120","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0125","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3109\/10428194.2014.953144","article-title":"Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States","volume":"56","author":"Nastoupil","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdx189_bb0130","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0135","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0140","article-title":"Updated 6year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy","volume":"122","author":"Seymour","year":"2013","journal-title":"Blood (ASH Abstract Meeting Abstract)"},{"key":"10.1093\/annonc\/mdx189_bb0145","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2012.44.8290","volume":"31","author":"Vitolo","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0150","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol E4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0155","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0160","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0165","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.leukres.2005.07.006","article-title":"Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment","volume":"30","author":"Arcaini","year":"2006","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdx189_bb0170","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma","volume":"17","author":"Gine","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0175","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdh406","article-title":"Predictive value of follicular lymphoma international prognostic index (FLIPI) in patients with follicular lymphoma at first progression","volume":"15","author":"Montoto","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0180","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0185","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1158\/1078-0432.CCR-13-1120","article-title":"A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine\u2013tositumomab","volume":"19","author":"Press","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx189_bb0190","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2009.08065.x","article-title":"Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients","volume":"149","author":"Arcaini","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx189_bb0195","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(15)00142-4","article-title":"A novel clinicogenetic prognostic score for follicular lymphoma","volume":"16","author":"Lopez-Guillermo","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0200","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0205","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2004-06-2298","article-title":"Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment","volume":"105","author":"Glas","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0210","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood-2004-07-2721","article-title":"High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma","volume":"105","author":"Bjorck","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0215","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2008-02-140616","article-title":"Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances","volume":"113","author":"Cheung","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0220","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1158\/0008-5472.CAN-10-2460","article-title":"Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis","volume":"70","author":"Cheung","year":"2010","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdx189_bb0225","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/blood-2013-05-500595","article-title":"Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma","volume":"123","author":"Bouska","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/gcc.20617","article-title":"Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status","volume":"48","author":"Schwaenen","year":"2009","journal-title":"Genes Chromosom Cancer"},{"key":"10.1093\/annonc\/mdx189_bb0235","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdx189_bb0240","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdx189_bb0245","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","article-title":"BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0250","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2004-06-2490","article-title":"Quantitative PCR of bone marrow BCL2\/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma","volume":"105","author":"Rambaldi","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0255","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2008-05-154013","article-title":"The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival","volume":"112","author":"O'Shea","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0260","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.leu.2403802","article-title":"A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"19","author":"Davies","year":"2005","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdx189_bb0265","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1365-2141.2006.06232.x","article-title":"Absolute lymphocyte count predicts overall survival in follicular lymphomas","volume":"134","author":"Siddiqui","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx189_bb0270","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2007.06596.x","article-title":"Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas","volume":"137","author":"Behl","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx189_bb0275","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/bjh.13332","article-title":"Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi","volume":"169","author":"Marcheselli","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx189_bb0280","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3109\/10428194.2011.637211","article-title":"The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma","volume":"53","author":"Wilcox","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdx189_bb0285","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12185-014-1576-0","article-title":"Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma","volume":"99","author":"Kumagai","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1093\/annonc\/mdx189_bb0290","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1182\/blood-2014-06-583369","article-title":"Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma","volume":"125","author":"Mir","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0295","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1200\/JCO.2014.57.5092","article-title":"Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies","volume":"33","author":"Kelly","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0300","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-14-3253","article-title":"The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC Cancer Agency and the Lymphoma Study Association","volume":"21","author":"Kridel","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx189_bb0305","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","article-title":"Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)","volume":"106","author":"Farinha","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0310","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1158\/1078-0432.CCR-07-0778","article-title":"A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone","volume":"13","author":"Taskinen","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx189_bb0315","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/1078-0432.CCR-06-1734","article-title":"CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma","volume":"13","author":"Wahlin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx189_bb0320","doi-asserted-by":"crossref","first-page":"e281.","DOI":"10.1038\/bcj.2015.1","article-title":"PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival","volume":"5","author":"Yang","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1093\/annonc\/mdx189_bb0325","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2009-07-235598","article-title":"The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation","volume":"115","author":"Farinha","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0330","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0335","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1078-0432.154.11.1","article-title":"Increased vascularization predicts favorable outcome in follicular lymphoma","volume":"11","author":"Koster","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx189_bb0340","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2006.10.5833","article-title":"Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group","volume":"25","author":"Klapper","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0345","doi-asserted-by":"crossref","first-page":"e0127589.","DOI":"10.1371\/journal.pone.0127589","article-title":"Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy","volume":"10","author":"Chu","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1093\/annonc\/mdx189_bb0350","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0355","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/djp369","article-title":"Detecting an overall survival benefit that is derived from progression-free survival","volume":"101","author":"Broglio","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdx189_bb0360","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0365","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.beha.2011.04.001","article-title":"Perspective of clinical research in follicular NHL: interaction between science and industry","volume":"24","author":"Fine","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1093\/annonc\/mdx189_bb0370","first-page":"136","author":"Morschhauser","year":"2013"},{"key":"10.1093\/annonc\/mdx189_bb0375","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1200\/JCO.2009.26.8748","article-title":"Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date?","volume":"28","author":"Illidge","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0380","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"10.1093\/annonc\/mdx189_bb0385","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1200\/JCO.2006.10.4323","article-title":"End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group","volume":"25","author":"Sargent","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0390","doi-asserted-by":"crossref","first-page":"8664","DOI":"10.1200\/JCO.2005.01.6071","article-title":"Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials","volume":"23","author":"Sargent","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0395","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.2003.08.072","article-title":"End points and United States Food and Drug Administration approval of oncology drugs","volume":"21","author":"Johnson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0400","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/JCO.2009.22.7819","article-title":"Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival\u2013a study from the groupe d'etude des lymphomes de l'adulte","volume":"28","author":"Bachy","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0405","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.1994.12.7.1343","article-title":"Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma","volume":"12","author":"Lopez-Guillermo","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0410","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1093\/annonc\/mdq615","article-title":"Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points","volume":"22","author":"Lee","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0415","article-title":"Role of different frontline regimens in achieving complete response in follicular lymphoma: a meta-analysis of CR rate and its relation to hazard rate for disease progression","volume":"108","author":"Saville","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdx189_bb0420","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0425","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0430","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0435","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3816\/CLM.2008.n.040","article-title":"Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?","volume":"8","author":"Janikova","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1093\/annonc\/mdx189_bb0440","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/annonc\/mdt562","article-title":"The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)","volume":"25","author":"Luminari","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0445","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0450","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3816\/CLM.2007.n.005","article-title":"Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma","volume":"7","author":"Zinzani","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1093\/annonc\/mdx189_bb0455","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1093\/annonc\/mdx189_bb0460","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.3324\/haematol.2015.132811","article-title":"Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi","volume":"101","author":"Luminari","year":"2016","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdx189_bb0465","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","article-title":"Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial","volume":"20","author":"Galimberti","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx189_bb0470","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","article-title":"Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program","volume":"122","author":"Ladetto","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx189_bb0475","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.2009.25.0852","article-title":"BCL-2\/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed\/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0480","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdx189_bb0485","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3109\/10428194.2012.711830","article-title":"The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma","volume":"54","author":"Yost","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdx189_bb0490","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1093\/annonc\/mdx189_bb0495","article-title":"Development of a measure of health-related quality of life for non-Hodgkin\u2019s lymphoma clinical research: the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)","volume":"106","author":"Cella","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdx189_bb0500","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clml.2016.01.001","article-title":"Differences in quality of life between bendamustine-rituximab and R-CHOP\/R-CVP in patients with previously untreated advanced indolent non-Hodgkin lymphoma or mantle cell lymphoma","volume":"16","author":"Burke","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1093\/annonc\/mdx189_bb0505","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2014.57.6801","article-title":"Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT)","volume":"33","author":"Wagner","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx189_bb0510","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jval.2014.12.017","article-title":"Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma","volume":"18","author":"Chen","year":"2015","journal-title":"Value Health"},{"key":"10.1093\/annonc\/mdx189_bb0515","doi-asserted-by":"crossref","first-page":"978391.","DOI":"10.1155\/2012\/978391","article-title":"Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare","volume":"2012","author":"Griffiths","year":"2012","journal-title":"J Cancer Epidemiol"},{"key":"10.1093\/annonc\/mdx189_bb0520","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/erp.12.57","article-title":"Cost-effectiveness of rituximab in follicular lymphoma","volume":"12","author":"Johnston","year":"2012","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1093\/annonc\/mdx189_bb0525","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.29372","article-title":"Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: a cost-effectiveness analysis","volume":"121","author":"Prica","year":"2015","journal-title":"Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419352275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419352275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/9\/2094\/24169666\/mdx189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T13:48:29Z","timestamp":1658929709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419352275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":104,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0923753419352275"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx189","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}